TechFlex is dedicated to assisting startups in the Series A and Seed money stages to achieve their objectives through a structured and supportive framework. Our approach focuses on providing tailored solutions that address the unique challenges faced by early-stage companies.
TechFlex is the catalyst for success in the medical device industry, offering comprehensive support to growing companies. With expertise spanning from initial concept to market entry, TechFlex provides tailored solutions, cutting-edge technologies, and regulatory guidance.
Today, Route 92 Medical has announced positive results from its SUMMIT MAX randomised controlled trial (RCT) comparing the efficacy and safety of the HiPoint reperfusion system, including the super-bore 0.088-inch HiPoint 88 aspiration catheter, to a conventional 0.074-inch catheter.
Read the full article at: neuronewsinternational.com
